WO1995009623A1

WO1995009623A1 - Anti-allergic, anti-inflammatory compounds, compositions and uses

Info

Publication number: WO1995009623A1
Application number: PCT/US1994/010767
Authority: WO
Inventors: Siegfried Benjamin Christensen, Iv; Kevin Scott Webb
Original assignee: Smithkline Beecham Corporation
Priority date: 1993-10-01
Filing date: 1994-09-23
Publication date: 1995-04-13
Also published as: AU7957794A

Abstract

Novel cyclohexanes of formula (I) are described herein. They inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV.

Description

-WTI-A l-ERGIC . AISTTI-INFLAMMATORY COMPOUNDS , COMPOSITIONS AND USES

Field of Invention

The present invention relates to novel compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).

Background of the Invention

Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyperreactivity of the respiratory tract to external stimuli.

Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of the disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease.

One such way is by elevating levels of cAMP (adenosine cyclic 3',5'- monophosphate). Cyclic AMP has been shown to be a second messenger mediating the biologic responses to a wide range of hormones, neurotransmitters and drugs; [Krebs Endocrinology Proceedings of the 4th International Congress Excerpta

Medica, 17-29, 1973]. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated, which converts Mg⁺2-ATP to cAMP at an accelerated rate.

Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocyte and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit phosphodiesterase should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of cAMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs). It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE) isozyme, PDE IN, is responsible for cAMP breakdown in airway smooth muscle and inflammatory cells. [Torphy, "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd., 1989]. Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IN inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IN inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.

The compounds of this invention also inhibit the production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to human acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis, in addition to a number of autoimmune diseases, such as multiple sclerosis, autoimmune diabetes and systemic lupus erythematosis. AIDS results from the infection of T lymphocytes with Human

Immunodeficiency Virus (HIN). At least three types or strains of HIN have been identified, i.e., HIV-1, HIN-2 and HIV-3. As a consequence of HIN infection, T- cell-mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIN entry into the T lymphocyte requires T lymphocyte activation. Viruses such as HIN-1 or HIN-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HTV gene expression and/or HIV replication.

Cytokines, specifically TNF, are implicated in activated T-cell-mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by inhibition of cytokine production, notably TNF, in an HIV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HTV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HTV infection. Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HIV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al., The Immunopathogenesis of HTV Infection, Advances in Immunology, Vol. 57, 1989]. Monokines, such as TNF, have been shown to activate HT replication in monocytes and/or macrophages [See Poli et al, Proc. Natl. Acad. Sci., 87:782-784, 1990], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells.

TNF has also been implicated in various roles with other viral infections, such as the cytomegalovirus (CMV), influenza virus, adenovirus, and the herpes virus for similar reasons as those noted.

TNF is also associated with yeast and fungal infections. Specifically Candida albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al., Infection and Immunity, 58(9):2750-54, 1990; and Jafari et al, Journal of Infectious Diseases, 164:389-95, 1991. See also Wasan et al., Antimicrobial Agents and Chemotherapy, 35,(10):2046-48, 1991; and Luke et al, Journal of Infectious Diseases, 162:211- 214,1990].

The ability to control the adverse effects of TNF is furthered by the use of the compounds which inhibit TNF in mammals who are in need of such use. There remains a need for compounds which are useful in treating TNF-mediated disease states which are exacerbated or caused by the excessive and/or unregulated production of TNF.

Summary of the Invention This invention relates to the novel compounds of Formula (I) as shown below, useful in the mediation or inhibition of the enzymatic activity (or catalytic activity) of phosphodiesterase IV (PDE IV). These compounds also have Tumor Necrosis Factor (TNF) inhibitory activity.

This invention also relates to the pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. The invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of PDE FV in mammals, including humans, which comprises administering to a mammal in need thereof an effective amount of a compound of Formula (I) as shown below.

The invention further provides a method for the treatment of allergic and inflammatory disease which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I).

The invention also provides a method for the treatment of asthma which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of Formula (I). This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment, an effective TNF inhibiting amount of a compound of Formula (I). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto. This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HTV), which comprises administering to such human an effective TNF inhibiting amount of a compound of Formula (I).

Compounds of Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.

In addition, compounds of Formula (I) are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo.

Novel compounds of this invention are represented by Formula (I):

wherein:

R! is -(CR4R5)nC(O)O(CR4R5)m 6, -(CR4R5)nC(O)NR4(CR4R5)mR6, - (CR4R5)_nO(CR4R5)_mR6, or -(CR4R5)_rR6 wherein the alkyl moieties may be optionally substituted with one or more halogens; m is 0 to 2; n is 1 to 4; r is 0 to 6;

R4 and R5 are independently selected hydrogen or C 1-2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, Cγ.n polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties is unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in

-(CR4R5)nO(CR4R5)mR6;

X is YR2, halogen, nitro, NR4R5, or formyl amine; Y is O or S(O)_m'; m' is 0, 1, or 2;

X2 is O or NR8; X3 is hydrogen or X; R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; R3 is C1-4 alkyl, fluoro-substituted C1-4 alkyl, CH2NHC(O)C(O)NH2, -

CH=CR8'R8', cyclopropyl optionally substituted by R8', CN, CH2OR8, CH2NR8R10, C(Z')H, C(O)ORs, C(O)NR8Rl0, or OCRs^*;

Z is C(Y')Rl4. C(O)ORi4, C(Y')NRiθRl4, C(NRiθ)NRiθRl4, CN, C(NOR8)Rl4, C(O)NR8NR8C(O)R8, C(O)NRsNRiθRl4, C(NORl4)R8, C(NR8)NRioRl4, C(NRi4)NRδR8 C(NCN)NRiθRl4, C(NCN)SR9, (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or 5-triazolyl[l,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[l,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl); wherein all of the heterocylic ring systems may be optionally substituted one or more times by R7; V is O or S;

Z^* is O, NR9, NOR8, NNR8R8, NCN, C(-CN)2, CRδCN, CR8NO2, CR8C(O)OR9, CR8C(O)NR8R8, C(-CN)NO2, C(-CN)C(O)OR9, or C(-CN)C(O)NR8R8;

R7 is -(CR4R5) Rl2 or C . alkyl wherein the R12 or C\.^ alkyl group is optionally substituted one or more times by Ci-2 alkyl optionally substituted by one to three fluorines, -F, -Br, -Cl, -NO2, -Si(R4)3, -NRi()Rl l_> -C(O)R8, -CO2R8, - OR8, -CN, -C(O)NRιoRll, -OC(O)NRιoRll, -OC(O)Rs, -NRιoC(O)NRιoRll, -NRιoC(O)Rn, -NRi()C(O)OR9, -NRιoC(O)Ri3, -C(NRιo)NRiθRll,

-C(NCN)NRιoRll, -C(NCN)SR9, -NRιoC(NCN)SR9 , -NRιoC(NCN)NRιoRll, -NRιoS(O)₂R9, -S(O)_m'R9, -NRiθC(O)C(O)NRlθRl l, -NRι₀C(O)C(O)Rι₀, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl; q is O, 1, or 2; R12 is C3-7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2- imidazolyl), thiazolyl, triazolyl, pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), (4- or 5-thiazolyl), quinolinyl, naphthyl, or phenyl;

R8 is independently selected from hydrogen or R9;

R ' is R8 or fluorine; R9 is Cj_4 alkyl optionally substituted by one to three fluorines;

RlO is ORδ or Rn; R i is hydrogen, or C1.4 alkyl optionally substituted by one to three fluorines; or when Rio and Rl l are as NRio l 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S; R13 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cj_2 alkyl groups;

Rj4 is hydrogen or R7; or when R8 and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S;

Rχ5 is C(O)Ri4, C(O)NR4Rl4, S(O)2R7. or S(O)2NR4Ri4; provided that:

(f) when R12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N- piperazinyl, N-piperidinyl, or N-morpholinyl, then q is not 1; or a pharmaceutically acceptable salts thereof.

Detailed Description of the Invention

This invention also relates to a method of mediating or inhibiting the enzymatic activity (or catalytic activity) of PDE IN in a mammal in need thereof and to inhibiting the production of TΝF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I).

Phosphodiesterase IN inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE rV inhibitors are useful in the treatment of diabetes insipidus and central nervous system disorders such as depression and multi-infarct dementia.

The viruses contemplated for treatment herein are those that produce TΝF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TΝF inhibitors of Formula (I). Such viruses include, but are not limited to HIV-1, HIN-2 and HIN-3, cytomegalovirus (CMN), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, Herpes zoster and Herpes simplex. This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIN), which comprises administering to such mammal an effective TΝF inhibiting amount of a compound of Formula (I).

The compounds of this invention may also be used in association with the veterinary treatment of animals, other than in humans, in need of inhibition of TΝF production. TΝF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FTV) or other retroviral infection such as equine infectious anemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.

The compounds of this invention are also useful in treating yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TΝF or will elicit TΝF production in vivo. A preferred disease state for treatment is fungal meningitis. Additionally, the compounds of Formula (I) may be administered in conjunction with other drugs of choice for systemic yeast and fungal infections. Drugs of choice for fungal infections, include but are not limited to the class of compounds called the polymixins, such as Polymycin B, the class of compounds called the imidazoles, such as clotrimazole, econazole, miconazole, and ketoconazole; the class of compounds called the triazoles, such as fluconazole, and itranazole, and the class of compound called the Amphotericins, in particular Amphotericin B and liposomal Amphotericin B. The compounds of Formula (I) may also be used for inhibiting and/or reducing the toxicity of an anti-fiingal, anti-bacterial or anti-viral agent by administering an effective amount of a compound of Formula (I) to a mammal in need of such treatment. Preferably, a compound of Formula (I) is administered for inhibiting or reducing the toxicity of the Amphotericin class of compounds, in particular Amphotericin B. Preferred compounds are as follows:

When Ri for the compounds of Formula (I) is an alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluorines. The preferred halo-substituted alkyl chain length is one or two carbons, and most preferred are the moieties -CF3, - CH2F, -CHF2, -CF2CHF2, -CH2CF3, and -CH2CHF2. Preferred Ri substitutents for the compounds of Formula (I) are CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4- 6 cycloalkyl, C7-H polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci-2 alkyl optionally substituted by 1 or more fluorines, -(CH2)l-3C(O)O(CH2)0-2CH3, -(CH2)l-3O(CH2)0-2CH3, and -(CH2)2-4OH.

When the Ri term is (CR4R5), the R4 and R5 terms are independently hydrogen or alkyl. This allows for branching of the individual methylene units as (CR4R5)n or (CR4R5)_m; each repeating methylene unit is independent of the other, e.g., (CR4R5)n wherein n is 2 can be -CH2CH(-CH3)-, for instance. The individual hydrogen atoms of the repeating methylene unit or the branching hydrocarbon can optionally be substituted by fluorine independent of each other to yield, for instance, the preferred Ri substitutions, as noted above. When Ri is a C7-I l polycycloalkyl, examples are bicyclo[2.2.1]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo[5.2.1.0²>6]decyl, etc. additional examples of which are described in Saccamano et al, WO 87/06576, published 5 November 1987, whose disclosure is incorporated herein by reference in its entirety. Z is preferably C(O)R8, C(O)OR8, C(O)NRδR8, C(NR8)NRsR8, CN, C(NOR8)R8, C(O)NRsNR8C(O)R8, C(NR8)NRδR8, C(NCN)NR8R8,

C(NCN)SR9, (1-, 4- or 5-{R8}-2-imidazolyl), (1-, 4- or 5-{R8}-3-pyrazolyl), (1-, 2- or 5-{R8)-4-triazolyl[l,2,3]), (1-, 2-, 4- or 5-{R8}-3-triazolyl[l,2,4]), (1- or 2- {R8}-5-tetrazolyl), (4- or 5-{Rs}-2-oxazolyl), (3- or 4-{Rs}-5-isoxazolyl), (3- {R8}-5-oxadiazolyl[l,2,4]), (5-{Rs}-3-oxadiazolyl[l,2,4]), (5- {R8}-2-oxadiazolyl[l,3,4]), (5-{R8}-2-thiadiazolyl[l,3,4]), (4- or 5-{R8)-2-thiazolyl), (4- or 5-{R8}-2-oxazolidinyl), (4- or 5-{R8}-2-thiazolidinyl),(l-, 4- or 5-{R8}-2-imidazolidinyl); most preferred are those compounds wherein the R8 group of Z is R4. Preferred X groups for Formula (I) are those wherein X is YR2 and Y is oxygen. The preferred X2 group for Formula (I) is that wherein X2 is oxygen. The preferred X3 group for Formula (I) is that wherein X3 is hydrogen. Preferred R2 groups, where applicable, is a Cl-2 alkyl optionally substituted by 1 or more halogens. The halogen atoms are preferably fluorine and chlorine, more preferably fluorine. More preferred R2 groups are those wherein R2 is methyl, or the fluoro- substituted alkyls, specifically a Cl-2 alkyl, such as a -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are the -CHF2 and -CH3 moieties. Preferred R3 moieties are C(O)NH2, C≡CRs, CN, C(Z')H, CH2OH, CH2F,

CF2H, and CF3. More preferred are G≡CH and CN. Z' is preferably O or NOR8-

Preferred R7 moieties include optionally substituted -(CH2)l- 2(cyclopropyl), -(CH2)0-2(cyclobutyl), -(CH2)0-2(cyclopentyl), -(CH2)0- 2(cyclohexyl), -(CH2)0-2(2-, 3- or 4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4- morpholinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl;

Preferred rings when Rio and Rl l in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 2-(R8)-l-imidazolyl, 1 -pyrazolyl,

3-(R8)-l-pyrazolyl, 1-triazolyl, 2-triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetrazolyl, 5-(R8)-2-tetrazolyl, 1-tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(R8)-l-piperazinyl, orpyrrolyl ring.

Preferred rings when Rs and R14 in the moiety -NRsRl4 together with the nitrogen to which they are attached may form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1-imidazolyl, 1 -pyrazolyl, 1 -triazolyl, 2-triazolyl, 1-tetrazolyl, 2-tetrazolyl, morpholinyl, piperazinyl, and pyrrolyl. The respective rings may be additionally substituted, where applicable, on an available nitrogen or carbon by the moiety R7 as described herein for Formula (I). Illustrations of such carbon substitutions includes, but is not limited to, 2-(R7)-l-imidazolyl, 4-(R7)-l-imidazolyl, 5-(R7)-l-imidazolyl, 3-(R7)-l -pyrazolyl, 4-(R7)-l-pyrazolyl, 5-(R7)-l-pyrazolyl, 4-(R7)-2-triazolyl, 5-(R7)-2-triazolyl, 4-(R7)-l -triazolyl, 5-(R7)-l-triazolyl, 5-(R7)-l-tetrazolyl, and 5-(R7)-2-tetrazolyl. Applicable nitrogen substitution by R7 includes, but is not limited to, l-(R7)-2-tetrazolyl, 2-(R7)-l-tetrazolyl, 4-(R7)-l -piperazinyl. Where applicable, the ring may be substituted one or more times by R7. Preferred groups for NR8R14 which contain a heterocyclic ring are 5-(Ri4)- 1-tetrazolyl, 2-(Ri4)-l-imidazolyl, 5-(Rl4)-2-tetrazolyl, 4-(Ri4)-l-piperazinyl, or 4-(R 15)- 1 -piperazinyl. Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or

5-ρyrazolyl), (4- or 5-triazolyl[ 1,2,3]), (3- or 5-triazolyl[l,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[ 1,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl). When the R7 group is optionally substituted by a heterocyclic ring such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, or thiazolyl, the heterocyclic ring itself may be optionally substituted by R8 either on an available nitrogen or carbon atom, such as l-(R8)-2-imidazolyl, l-(R8)-4-imidazolyl, l-(R8)-5-imidazolyl, l-(R8)-3-pyrazolyl, l-(R8)-4-pyrazolyl, l-(R8)-5-pyrazolyl, l-(R8)-4-triazolyl, or l-(R8)-5-triazolyl. Where applicable, the ring may be substituted one or more times by R8-

Preferred are those compounds of Formula (I) wherein Rj is -CH2- cyclopropyl, -CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl or -Cl-2 alkyl optionally substituted by 1 or more fluorines, and -(CH2)2-4 OH; R2 is methyl or fluoro-substituted alkyl, R3 is CN or C≡CR8; and X is YR2.

Most preferred are those compounds wherein Ri is -CH2-cyclopropyl, cyclopentyl, methyl or CF2H; R3 is CN or C≡CH; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl.

A preferred subgenus of Formula (I) are the compounds of Formula (la)

wherein:

Rl is CH2-cyclopropyl, CH2-C5-6 cycloalkyl, C4-6 cycloalkyl, C7-H polycycloalkyl, (3- or 4-cyclopentenyl), phenyl, tetrahydrofuran-3-yl, benzyl or Ci- 2 alkyl optionally substituted by 1 or more fluorines,

-(CH2)1-3C(O)O(CH2)0-2CH3, -(CH2)l-3θ(CH )θ-2CH3, and -(CH2)2-4θH; X is YR2_. halogen, nitro, NR4R5, or formyl amine;

Y is O or S(O)_m'; m' is O, 1, or 2;

R2 is -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; R3 is C1-4 alkyl, halo-substituted C1-4 alkyl, CH2NHC(O)C(O)NH2, CN, CH2OR8, C(Z')H, C(O)OR8, C(O)NRδRl0, or C≡CRδ; Z' is O or NOR8;

Z is C(Y')Rl4, C(O)ORl4, C(Y')NRlθRl4, C(NRi₀)NRlθRl4, CN, C(NOR8)Rl4, C(O)NR8NRsC(O)R8, C(O)NRsNRioRl4, C(NORi4)R8, C(NR8)NRιoRl4, C(NRi4)NR8R8 C(NCN)NRιoRl4, C(NCN)SR9, (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or

5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[l,2,4]), (2-oxadiazolyl[ 1,3,4]), (2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl); wherein all of the heterocylic ring systems may be optionally substituted one or more times by R7; Y^* is O or S;

R7 is -(CR4R5)qRl2 or C . alkyl wherein the R12 or C . alkyl group is optionally substituted one or more times by Cl-2 alkyl optionally substituted by one to three fluorines, -F, -Br, -Cl, -NO2, -Si(R4)3, -NRIORJ I, -C(O)R8, -CO2R8, - OR8, -CN, -C(O)NRiθRll, -OC(O)NRiθRll, -OC(O)R8, -NRιoC(O)NRιoRll, -NRlθC(O)Rl l, -NRiθC(O)OR9, -NRlθC(O)Ri3, -C(NRio)NRiθRl l, -C(NCN)NRiθRl l, -C(NCN)SR9, -NRIQC(NCN)SR9 , -NRιoC(NCN)NRιoRll, -NRioS(O)₂R9, -S(0)m'R9, -NRι₀C(O)C(O)NRι₀Rl l, -MRiθC(0)C(0)Riθ, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl; q is O, l, or 2;

Rl2 is C3-7 cycloalkyl, (2-, 3- or 4-pyridyl), (1- or 2-imidazolyl), piperazinyl, morpholinyl, (2- or 3-thienyl), (4- or 5-thiazolyl), or phenyl;

R is independently selected from hydrogen or R9;

R9 is Cι_4 alkyl optionally substituted by one to three fluorines;

RiO is ORs or Rii;

Rl 1 is hydrogen or C 1.4 alkyl optionally substituted by one to three fluorines; or when Rio and Rl 1 are as NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;

Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C -.2 alkyl groups;

R 4 is hydrogen or R7; or when R8 and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S; R₁₅ is C(O)Ri4, C(O)NR4Ri4, S(O)2R7, or S(O)2NR4Rl4. provided that: a) when R12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N- piperazinyl, N-piperidinyl, or N-morpholinyl, then q is not 1; or a pharmaceutically acceptable salts thereof. Exemplified preferred compounds of Formula (I) are:

2-carbomethoxy-5-cyano-5-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexan- 1 -one.

It will be recognized that some of the compounds of Formula (I) may exist in both racemic and optically active forms; some may also exist in distinct diastereomeric forms possessing distinct physical and biological properties. All of these compounds are considered to be within the scope of the present invention. Compounds of Formula (I) may exist in a tautomeric form, such as the enol form. This may be represented by the =O being exocyclic to the cyclohexane ring

(or ^R3 ) as contrasted to the endocyclic or -C(-OH)=C(-R)- moiety wherein the cyclohexane ring is now unsaturated in the 1-2 position, i.e. cyclohex-

1-ene , or ^R3 and R is Z in Formula (I). It is also recognized that the 2- position of the ring in the exocyclic form can be substituted (R) such as in the compounds of Formula (I).

The term "C1-.3 alkyl", "C1.4 alkyl", "Cι_₆ alkyl" or "alkyl" groups as used herein is meant to include both straight or branched chain radicals of 1 to 10, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, isobutyl, terr-butyl, and the like.

"Alkenyl" means both straight or branched chain radicals of 1 to 6 carbon lengths, unless the chain length is limited thereto, including but not limited to vinyl, 1-propenyl, 2-propenyl, 2-propynyl, or 3-methyl-2-propenyl.

The term "cycloalkyl" or "cycloalkyl alkyl" means groups of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl, or cyclohexyl.

"Aryl" or "aralkyl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms, such as phenyl, benzyl, phenethyl, or naphthyl. Preferably the aryl is monocyclic, i.e, phenyl. The alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.

"Heteroaryl" means an aromatic ring system containing one or more heteroatoms, such as imidazolyl, triazolyl, oxazolyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, furanyl, or thienyl. "Halo" means all halogens, i.e., chloro, fluoro, bromo, or iodo.

"Inhibiting the production of IL-1" or "inhibiting the production of TNF" means: a) a decrease of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels by inhibition of the in vivo release of IL-1 by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcriptional level, of excessive in vivo IL-1 or TNF levels, respectively, in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of IL-1 or TNF levels as a postranslational event.

The phrase "TNF mediated disease or disease states" means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL- 6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise. Preferably TNF-α is inhibited.

"Cytokine" means any secreted polypeptide that affects the functions of cells, and is a molecule which modulates interactions between cells in immune, inflammatory, or hematopoietic responses. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them. The cytokine inhibited by the present invention for use in the treatment of a HIV- infected human must be a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HTV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. Preferrably, his cytokine is TNF- α.

All of the compounds of Formula (I) are useful in the method of inhibiting the production of TNF, preferably by macrophages, monocytes or macrophages and monocytes, in a mammal, including humans, in need thereof. All of the compounds of Formula (I) are useful in the method of inhibiting or mediating the enzymatic or catalytic activity of PDE rV and in treatment of disease states mediated thereby.

METHODS OF PREPARATION:

Preparing compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined in the Examples, infra. The preparation of any remaining compounds of Formula (I) not described therein may be prepared by the analogous processes disclosed herein which comprise: a) for compounds wherein X and X3 are other than Br, I, NO2, amine, formyl amine, or S(O)m' when m' is 1 or 2, reacting a compound of Formula (2)

wherein Ri represents Rl as defined in relation to Formula (I) or a group convertable to Ri and X, X2 and X3 represent X, X2 and X3 as defined in relation to Formula (I) or a group convertable to X, X2 or X3 and R2 represents R2 as defined in relation to Formula (I) or a group convertable to R2, with a suitable base (such as LDA, LiHMDS or KHMDS) in a suitable non-reacting solvent followed by reaction with, e.g., formaldehyde, provides compounds of the Formula (3)

wherein Ri6 is H, followed, when appropriate, by protecting the alcohol (R = protecting group). Michael-type reaction of such a compound of the Formula (3) with the appropriate precursor of R3 or a group convertable to R3 then provides a compound of the Formula (4)

wherein R3 represents R3 as defined in relation to Formula (I) or a group convertable to R3; for example, use of excess diethylaluminum cyanide provides a compound of the Formula (4) wherein Ri represents Rl as defined in relation to Formula (I) or a group convertable to Rl and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3 and R3 is CN. After appropriate protection of the ketone of such compounds of the Formula (4) as, e.g., a dimethylketal or a dioxolane, followed by cleavage of the Ri6 protecting group, if present, oxidation of the alcohol to the aldehyde by, e.g., Swern oxidation, and further oxidation with, e.g., methanolic potassium hydroxide and iodine, then provides compounds of the Formula (5)

wherein Ri represents Rl as defined in relation to Formula (I) or a group convertable to Rl and R3 represents R3 as defined in relation to Formula (I) or a group convertable to R3 and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to Formula (I) or a group convertable to X3, =Z" is a ketone protecting group, such as a dimetiiylketal or a dioxolane, and Z"' is CHO or COOR 16- Ketone deprotection of such compounds of the Formula (5) then provides the corresponding compounds of the Formula (I) wherein Rl represents Rl as defined in relation to Formula (I) or a group convertable to Rl and R3 represents R3 as defined in relation to Formula (I) or a group convertable to R3 and X represents X as defined in relation to Formula (I) or a group convertable to X and X3 represents X3 as defined in relation to

Formula (I) or a group convertable to X3 and =Z" is a ketone. Prior to deprotection of the =Z" ketone protecting group, functional group manipulation of the CHO or COOR16 groups, in some cases with appropriate protection and deprotection of chemically sensitive R3 group functionality, into other Z groups as defined in Formula (I) can be accomplished by the standard methods known to one of skill in the art; for example, some such manipulations of the COOR16 group can be accomplished by the processes described in U.S. application serial number 862,030 filed 2 April 1992 and its corresponding continuation-in-part application USSN 968,762 filed 30 October 1992; such manipulations are then followed by deprotection of the =Z" ketone protecting group, and, where applicable, deprotection of chemically sensitive R3 group functionality. Alternatively, reacting a compound of the Formula (6)

wherein Ri represents Ri as defined in relation to Formula (I) or a group convertable to Rl and X, X2 and X3 represent X, X2 and X3 as defined in relation to Formula (I) or a group convertable to X, X2 or X3 and R2 and R3 represent R2 and R3 as defined in relation to Formula (I) or a group convertable to R2 or R3 andwherein X or X3 is other than Br, I, NO2, amino, or S(O)m'R2 when m' is 0, 1 or 2, with a suitable base in a suitable non-reacting solvent followed by reaction with a suitable acylating agent [e.g., LC(O)(O)qR7 wherein L is a leaving group] to provide compounds of the Formula (I) wherein Z is C(O)(O)qR7 and R3 is other than C(=Z')H; preparation of such compounds of Formula (I) wherein R3 is C(=Z')H proceeds in an analogous fashion from the compound of Formula (2) wherein =Z' is an aldehyde protecting group, such as a dimethylacetal or a dioxolane, followed by deprotection to the aldehyde and subsequent elaboration by standard procedures known to those of skill in the art to the remaining compounds of Formula (I) wherein Z' is other than O. b) Compounds of Formula (I) wherein X or X3 is formyl amine may be prepared by formylating, at the last step, a compound wherein =Z is a protected ketone and X is NH2-* obtained by removal of a protecting group from the amine functionality; such protective groups are well known to those skilled in the art, See Greene, T. and Wuts, P.G.M., Protecting Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons, New York (1991). c) Compounds of Formula (I) wherein X or X3 is Br or I may be prepared from a similarly deprotected amine by diazotization of the amine and diazonium displacement via Sandmeyer reaction. d) Compounds of Formula (I) wherein X or X3 is NO2 may be prepared from a similarly deprotected amine by oxidation of the amine to the nitro group.

- 18 -

SUBSTΓΠJTE SHEET (RULE 26) e) Compounds of Formula (I) wherein Y is S(O)m' when m' is 1 or 2 may be prepared from the compounds of Formula (I) wherein Y is S by oxidation of the SR2 moiety under conditions well known to those skilled in the art. Compounds of Formula (2) and (6) may be prepared in turn by the processes described in co-pending U.S. patent application filed on even date herewith and identified as P50199.

The following examples are set out to illustrate how to make the compounds of this invention and methods for determining associated therapeutic activity. These examples are not intended to limit the invention in any manner, their purpose is illustrative rather than limiting.

Example 1 Preparation of 2-carbomethoxy-5-cyano-5-(3-cyclopentyloxy-4- methoxyphenyl)-cyclohexan- 1 -one To a solution of 2,2,6,6-tetramethylpiperidine (1.8 milliliters (hereinafter

(mL), 10.6 millimoles (hereinafter mmol)) in tetrahydrofuran (20 mL) at 0°C under an argon atmosphere is added dropwise over 10 minutes (hereinafter min) n- butyllithium (4.7 mL of 2.25M solution, 10.6 mmol), the resulting solution is stirred for 30 min and then is cooled to -78°C. To this is added dropwise over 30 min a solution of 3-cyano-3-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan- 1-one (1.5 grams (hereinafter g), 4.83 mmol) in tetrahydrofuran (10 mL). After stirring for 1 hour (hereinafter h), methyl chloroformate (0.37 mL, 4.8 mmol) is added dropwise over 5 min. The mixture is allowed to warm slowly to room temperature and, after 1.25h, the mixture is concentrated under reduced pressure. The residue is poured into water and is extracted with methylene chloride. The organic extract is washed twice with water, once with brine, is dried (magnesiun sulfate) and concentrated under reduced pressure. The residue is purified by flash chromatography to afford the product..

METHODS OF TREATMENT In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. The compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylatic or therapeutic treatment of any disease state in a human or other mammal which is mediated by inhibition of PDE TV, such as but not limited to asthma, allergic, or inflammatory diseases. The compounds of Formula (I) are administered in an amount sufficient to treat such a disease in a human or other mammal.

For the purposes herein all methods of treatment and dosage regimens apply equally to both the compounds of Formula (I). In order to use a compound of Formula (I), or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

The amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.

The daily dosage regimen for oral administration is suitably about .001 mg/kg to lOOmg/kg, preferably 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity.

No toxic effects are expected when these compounds are administered in accordance with the present invention. UTILITY EXAMPLES

EXAMPLE A Inhibitory effect of compounds of Formula (T) on in vitro TNF production by human monocytes The inhibitory effect of compounds of Formula (I) on in vitro TNF production by human monocytes may be determined by the protocol as described in Badger et al, EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990.

EXAMPLE B Two models of endotoxic shock have been utilized to determine in vivo TNF activity for the compounds of Formula (I). The protocol used in these models is described in Badger et al, EPO published Application 0411 754 A2, February 6, 1991, and in Hanna, WO 90/15534, December 27, 1990.

The compound of Example 1 herein demonstrated a positive in vivo response in reducing serum levels of TNF induced by the injection of endotoxin.

EXAMPLE C Isolation of PDE Isozvmes The phosphodiesterase inhibitory activity and selectivity of the compounds of Formula (I) can be determined using a battery of five distinct PDE isozymes. The tissues used as sources of the different isozymes are as follows: 1) PDE lb, porcine aorta; 2) PDE Ic, guinea-pig heart; 3) PDE HI, guinea-pig heart; 4) PDE IV, human monocyte; and 5) PDE V (also called "la"), canine trachealis. PDEs la, lb, Ic and HI are partially purified using standard chromatographic techniques [Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990]. PDE IV is purified to kinetic homogeneity by the sequential use of anion-exchange followed by heparin-

Sepharose chromatography [Torphy et al, J. Biol. Chem., 267:1798-1804, 1992].

Phosphodiesterase activity is assayed as described in the protocol of Torphy and Cieslinski, Mol. Pharmacol., 37:206-214, 1990. Positive ICso's in the nanomolar to μM range for compounds of the workings examples described herein for Formula (I) have been demonstrated.

EXAMPLE D The ability of selected PDE IV inhibitors to increase cAMP accumulation in intact tissues is assessed using U-937 cells, a human monocyte cell line that has been shown to contain a large amount of PDE IV. To assess the activity of PDE TV inhibition in intact cells, nondifferentiated U-937 cells (approximately lO-*** cells/reaction tube) were incubated with various concentrations (0.01-1000 μM) of PDE inhibitors for one minute and lμM prostaglandin E2 for an additional four minutes. Five minutes after initiating the reaction, cells were lysed by the addition of 17.5% perchloric acid, the pH was neutralized by the addition of 1M potassium carbonate and cAMP content was assessed by RIA. A general protocol for this assay is described in Brooker et al, Radioimmunassay of cyclic AMP and cyclic GMP., Adv. Cyclic Nucleotide Res., 10: 1-33, 1979. The compounds of the working examples as described herein for Formula (I) have demonstrated a positive EC5QS in the μM range in the above assay.

Claims

What is claimed is:

1. A compound of Formula (I)

wherein:

Rl is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, - (CR4R5)_nO(CR4R5)_mR6, or -(CR4R5)_rR6 wherein the alkyl moieties may be optionally substituted with one or more halogens; m is 0 to 2; n is 1 to 4; r is 0 to 6;

R4 and R5 are independently selected hydrogen or Cl-2 alkyl; R6 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyCl-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-H polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclic moieties is unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group; provided that: a) when R6 is hydroxyl, then m is 2; or b) when R6 is hydroxyl, then r is 2 to 6; or c) when R is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl, or 2-tetrahydrothienyl, then m is 1 or 2; or d) when R6 is 2-tetrahydropyranyl, 2-tetrahydrothiopyranyl, 2-tetrahydrofuranyl,or 2-tetrahydrothienyl, then r is 1 to 6; e) when n is 1 and m is 0, then R6 is other than H in

-(CR4R5)nO(CR4R5)mR6;

X is YR2. halogen, nitro, NR4R5, or formyl amine; Y is O or S(O)m'; m' is 0, 1, or 2;

X2 is O or NR8; X3 is hydrogen or X; R2 is independently selected from -CH3 or -CH2CH3 optionally substituted by 1 or more halogens; s is 0 to 4; R3 is C 1 -4 alkyl, fluoro-substituted C 1 -4 alkyl, CH2NHC(O)C(O)NH2, -

CH=CR8'R8'. cyclopropyl optionally substituted by R&, CN, CH2OR8, CH2NR8RIO, C(Z')H, C(O)OR8, C(O)NR8Rl0, or C≡CRδ';

Z is C(Y')Rl4, C(O)ORi4, C(Y')NRιoRl4, C(NRio)NRioRl4, CN, C(NOR8)Rl4, C(O)NR8NR8C(O)R8, C(O)NRsNRιoRl4, C(NORi4)R8, C(NR8)NRiθRl4, C(NRi4)NRsR8 C(NCN)NRιoRl4, C(NCN)SR9, (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or 5-triazolyl[l,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[l,2,4]), (2-oxadiazolyl[l,3,4]), (2-thiadiazolyl[l,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl); wherein all of the heterocylic ring systems may be optionally substituted one or more times by R7;

Y' is O or S;

Z is O, NR9, NOR8, NNR8R8, NCN, C(-CN)2, CRδCN, CR8NO2, CR8C(O)OR9, CR8C(O)NR8R8, C(-CN)NO2, C(-CN)C(O)OR9, or C(-CN)C(O)NR8R8;

R7 is -(CR4R5)nRl2 or Cj.g alkyl wherein the R12 or C _6 alkyl group is optionally substituted one or more times by Cl-2 alkyl optionally substituted by one to three fluorines, -F, -Br, -Cl, -NO2, -Si(R4)3, -NRioRπ, -C(O)R8, -CO2R8, - OR8, -CN, -C(O)NRlθRll, -OC(O)NRiθRll, -OC(O)R8, -NRioC(O)NRιoRll, -NRiθC(O)Rn, -NRiθC(O)OR9, -NRκ)C(O)Ri3, -C(NRio)NRioRll,

-C(NCN)NRlθRll, -C(NCN)SR9, -NRiθC(NCN)SR9 , -NRioC(NCN)NRi()Rll, -NRioS(O)2R9, -S(O)_m ^*R9, -NRi₀C(O)C(O)NRiθRll, -NRι₀C(O)C(O)Rι₀, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, or tetrazolyl; q is O, 1, or 2; R12 is C3-7 cycloalkyl, (2-, 3- or 4-pyridyl), pyrimidyl, pyrazolyl, (1- or 2- imidazolyl), thiazolyl, triazolyl, pyrrolyl, piperazinyl, piperidinyl, morpholinyl, furanyl, (2- or 3-thienyl), (4- or 5-thiazolyl), quinolinyl, naphthyl, or phenyl;

R is independently selected from hydrogen or R9;

R ' is R8 or fluorine; R9 is C1.4 alkyl optionally substituted by one to three fluorines;

RlO is ORδ or Rπ; R 1 is hydrogen, or C _4 alkyl optionally substituted by one to three fluorines; or when Rio and Rl l are as NRloRl 1 they may together with the nitrogen form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S;

Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, and each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cι_2 alkyl groups; R14 is hydrogen or R7; or when R8 and R14 are as NR8R14 they may together with the nitrogen form a 5 to 7 membered ring optionally containing one or more additional heteroatoms selected from O, N, or S;

Ri5 is C(O)Ri4, C(O)NR4Rl4, S(O)2R7, or S(O)2NR4Rl4; provided that: (f) when R12 is N-pyrazolyl, N-imidazolyl, N-triazolyl, N-pyrrolyl, N- piperazinyl, N-piperidinyl, or N-morpholinyl, then q is not 1; or a pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 which is 2-carbόmethoxy-5- cyano-5-(3-cyclopentyloxy-4-methoxyphenyl)-cyclohexan-l-one.

3. A pharmaceutical composition comprising a compound of Formula

(I) according to claim 1 and a pharmaceutically acceptable excipient.

4. A method for treating an allergic or inflammatory state which method comprises administering to a subject in need thereof an effective amount of a compound of Formula (I) according to claim 1 alone or in combination with a pharmaceutically acceptable excipient.